James L Januzzi
Overview
Explore the profile of James L Januzzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
409
Citations
18692
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bonaca M, Lang N, Chen A, Amiri-Kordestani L, Lipka L, Zwiewka M, et al.
JACC CardioOncol
. 2025 Feb;
7(2):83-95.
PMID: 39967209
The development of novel treatments has improved cancer outcomes but may result in cardiovascular toxicities. Traditional approaches to clinical trial safety evaluation have limitations in their ability to detect signals...
2.
Juhasz V, Quinaglia T, Drobni Z, Heemelaar J, Neuberg D, Han Y, et al.
JACC CardioOncol
. 2025 Feb;
7(2):125-137.
PMID: 39967198
Background: In the STOP-CA (Statins to Prevent the Cardiotoxicity From Anthracyclines) trial, atorvastatin preserved the left ventricular ejection fraction among patients with lymphoma treated with anthracyclines. The protective mechanisms are...
3.
Goldenberg I, Ezekowitz J, Albert C, Alexis J, Anderson L, Behr E, et al.
Heart Rhythm
. 2025 Feb;
PMID: 39918486
The main function of the implantable cardioverter-defibrillator (ICD) is to protect against sudden cardiac death (SCD) due to ventricular tachyarrhythmia (VTA). Current guidelines provide a recommendation to implant a prophylactic...
4.
Goldenberg I, Ezekowitz J, Albert C, Alexis J, Anderson L, Behr E, et al.
J Card Fail
. 2025 Feb;
PMID: 39915204
The main function of the implantable cardioverter-defibrillator (ICD) is to protect against sudden cardiac death (SCD) due to ventricular tachyarrhythmia (VTA). Current guidelines provide a recommendation to implant a prophylactic...
5.
Yuzefpolskaya M, Schwartz S, Ladanyi A, Abraham J, Gale C, Grinstein J, et al.
J Card Fail
. 2025 Jan;
PMID: 39890014
Heart failure (HF) is associated with poor prognosis, especially when it progresses to cardiogenic shock (CS), where survival rates substantially decline. A key area of interest is the role of...
6.
Robles-Mezcua A, Januzzi J, Pavon-Moron F, Rodriguez-Capitan J, Lopez-Garrido M, Cruzado-Alvarez C, et al.
Biomed Pharmacother
. 2025 Jan;
183:117874.
PMID: 39889435
Treatment of heart failure and reduced ejection fraction (HFrEF) using angiotensin receptor-neprilysin inhibitor demonstrates beneficial effects on cardiac remodeling (CR). We assessed the impact of sacubitril/valsartan on the concentrations of...
7.
Tang W, Liu Y, Butler J, Del Prato S, Ezekowitz J, Ibrahim N, et al.
Circ Heart Fail
. 2025 Jan;
:e012200.
PMID: 39882614
Background: Objective indices of functional capacity in patients with diabetic cardiomyopathy and stage B heart failure (HF) have not been comprehensively defined. We sought to characterize the cardiopulmonary exercise characteristics...
8.
Marwick T, Lam C, Liu Y, Del Prato S, Rosenstock J, Butler J, et al.
Cardiovasc Diabetol
. 2025 Jan;
24(1):16.
PMID: 39806375
Background: Diabetic myocardial disorder (DbMD, evidenced by abnormal echocardiography or cardiac biomarkers) is a form of stage B heart failure (SBHF) at high risk for progression to overt HF. SBHF...
9.
Adusumalli S, McCarthy C, Magaret C, Rhyne R, Jaffer F, Januzzi J
Am J Cardiol
. 2025 Jan;
242:25-31.
PMID: 39778643
There are limited tools available to predict the long-term prognosis of persons with coronary chronic total occlusions (CTO). A previously described blood biomarker panel to predict cardiovascular (CV) events was...
10.
Petrie M, Udell J, Anker S, Harrington J, Jones W, Mattheus M, et al.
Eur J Heart Fail
. 2024 Dec;
PMID: 39725521
Aims: In the EMPACT-MI trial, empagliflozin reduced heart failure (HF) hospitalizations but not mortality in acute myocardial infarction (MI). Contemporary reports of clinical event rates with and without type 2...